EyePoint (EYPT) Current Deferred Revenue (2011 - 2025)
EyePoint (EYPT) posted Current Deferred Revenue of $5.1 million for Q1 2025, down 71.24% sequentially from $17.8 million in Q4 2024, and down 86.67% YoY from $38.4 million in Q1 2024.
EyePoint (EYPT) Current Deferred Revenue (2011 - 2025) Analysis & Trends
EyePoint has reported Current Deferred Revenue for 15 years, with the latest figure at $5.1 million in Q1 2025.
- Quarterly Current Deferred Revenue fell 86.67% year-over-year to $5.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $5.1 million (down 86.67% YoY) and the FY2024 annual result came in at $17.8 million, down 53.92% from the prior year.
- Current Deferred Revenue eased to $5.1 million in Q1 2025 per EYPT's latest filing, from $17.8 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $42.1 million in Q2 2023 and troughed at $973000.0 in Q1 2021.
- A 5-year average of $14.8 million and a median of $1.2 million in 2023 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2025: Current Deferred Revenue surged 3601.32% in 2023, then slumped 86.67% in 2025.
- Over 5 years, Current Deferred Revenue stood at $1.1 million in 2021, then grew by 12.72% to $1.2 million in 2022, then jumped by 3102.66% to $38.6 million in 2023, then slumped by 53.92% to $17.8 million in 2024, then plunged by 71.24% to $5.1 million in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $5.1 million, $17.8 million, and $26.0 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 5.12 Mn |
| Dec 31, 2024 | 17.78 Mn |
| Sep 30, 2024 | 26.00 Mn |
| Jun 30, 2024 | 33.34 Mn |
| Mar 31, 2024 | 38.38 Mn |
| Dec 31, 2023 | 38.59 Mn |
| Sep 30, 2023 | 39.84 Mn |
| Jun 30, 2023 | 42.08 Mn |
| Mar 31, 2023 | 1.24 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 1.17 Mn |
| Jun 30, 2022 | 1.14 Mn |
| Mar 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 1.07 Mn |
| Sep 30, 2021 | 1.04 Mn |
| Jun 30, 2021 | 1.01 Mn |
| Mar 31, 2021 | 973,000.00 |
| Dec 31, 2020 | 945,000.00 |
| Sep 30, 2020 | 300,000.00 |
| Mar 31, 2020 | 30,000.00 |